These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 26065893)

  • 1. γ-Secretase directly sheds the survival receptor BCMA from plasma cells.
    Laurent SA; Hoffmann FS; Kuhn PH; Cheng Q; Chu Y; Schmidt-Supprian M; Hauck SM; Schuh E; Krumbholz M; Rübsamen H; Wanngren J; Khademi M; Olsson T; Alexander T; Hiepe F; Pfister HW; Weber F; Jenne D; Wekerle H; Hohlfeld R; Lichtenthaler SF; Meinl E
    Nat Commun; 2015 Jun; 6():7333. PubMed ID: 26065893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma.
    Pont MJ; Hill T; Cole GO; Abbott JJ; Kelliher J; Salter AI; Hudecek M; Comstock ML; Rajan A; Patel BKR; Voutsinas JM; Wu Q; Liu L; Cowan AJ; Wood BL; Green DJ; Riddell SR
    Blood; 2019 Nov; 134(19):1585-1597. PubMed ID: 31558469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endogenous soluble receptors sBCMA and sTACI: biomarker, immunoregulator and hurdle for therapy in multiple myeloma.
    Meinl E; Krumbholz M
    Curr Opin Immunol; 2021 Aug; 71():117-123. PubMed ID: 34330018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single Site
    Huang HW; Chen CC; Lin KI; Hsu TL; Wong CH
    ACS Chem Biol; 2024 Jan; 19(1):153-161. PubMed ID: 38085681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human Plasmacytoid Dendritic Cells Display and Shed B Cell Maturation Antigen upon TLR Engagement.
    Schuh E; Musumeci A; Thaler FS; Laurent S; Ellwart JW; Hohlfeld R; Krug A; Meinl E
    J Immunol; 2017 Apr; 198(8):3081-3088. PubMed ID: 28283566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased BCMA expression in lupus marks activated B cells, and BCMA receptor engagement enhances the response to TLR9 stimulation.
    Kim J; Gross JA; Dillon SR; Min JK; Elkon KB
    Autoimmunity; 2011 Mar; 44(2):69-81. PubMed ID: 21250838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unveiling the link between genetic alterations in gamma secretase and BCMA surface density in multiple myeloma.
    Cowan AJ; Green DJ
    Br J Haematol; 2024 Feb; 204(2):391-392. PubMed ID: 38014717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic defects of gamma-secretase genes in a multiple myeloma patient with high and dysregulated BCMA surface density: A case report.
    Cattaneo I; Valgardsdottir R; Cavagna R; Spinelli O; Bartoletti-Stella A; Capellari S; Galli M; Golay J
    Br J Haematol; 2024 Feb; 204(2):571-575. PubMed ID: 37957838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nirogacestat: First Approval.
    Keam SJ
    Drugs; 2024 Mar; 84(3):355-361. PubMed ID: 38409573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-BCMA CAR-T cells therapy for a patient with extremely high membrane BCMA expression: a case report.
    Li D; Que Y; Ding S; Hu G; Wang W; Mao X; Wang Y; Li C; Huang L; Zhou J; Zhang W; Xiao M
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36137648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B-cell maturation antigen (BCMA) activation exerts specific proinflammatory effects in normal human keratinocytes and is preferentially expressed in inflammatory skin pathologies.
    Alexaki VI; Pelekanou V; Notas G; Venihaki M; Kampa M; Dessirier V; Sabour-Alaoui S; Stathopoulos EN; Tsapis A; Castanas E
    Endocrinology; 2012 Feb; 153(2):739-49. PubMed ID: 22166983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular membrane-based vesicles displaying a reconstructed B cell maturation antigen for multiple myeloma therapy by dual targeting APRIL and BAFF.
    He C; Zhang M; Liu L; Han Y; Xu Z; Xiong Y; Yan F; Su D; Chen H; Zheng Y; Cheng F
    Acta Biomater; 2022 Apr; 143():406-417. PubMed ID: 35218967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of B-Cell Maturation Antigen in the Biology and Management of, and as a Potential Therapeutic Target in, Multiple Myeloma.
    Sanchez E; Smith EJ; Yashar MA; Patil S; Li M; Porter AL; Tanenbaum EJ; Schlossberg RE; Soof CM; Hekmati T; Tang G; Wang CS; Chen H; Berenson JR
    Target Oncol; 2018 Feb; 13(1):39-47. PubMed ID: 29230672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma.
    Lee L; Bounds D; Paterson J; Herledan G; Sully K; Seestaller-Wehr LM; Fieles WE; Tunstead J; McCahon L; Germaschewski FM; Mayes PA; Craigen JL; Rodriguez-Justo M; Yong KL
    Br J Haematol; 2016 Sep; 174(6):911-22. PubMed ID: 27313079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. γ-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation.
    Chen H; Yu T; Lin L; Xing L; Cho SF; Wen K; Aardalen K; Oka A; Lam J; Daley M; Lu H; Munshi N; Anderson KC; Tai YT
    Blood Cancer J; 2022 Aug; 12(8):118. PubMed ID: 35973981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of proteoglycans as the APRIL-specific binding partners.
    Ingold K; Zumsteg A; Tardivel A; Huard B; Steiner QG; Cachero TG; Qiang F; Gorelik L; Kalled SL; Acha-Orbea H; Rennert PD; Tschopp J; Schneider P
    J Exp Med; 2005 May; 201(9):1375-83. PubMed ID: 15851487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the receptor BCMA as a biomarker in systemic lupus erythematosus patients.
    Salazar-Camarena DC; Palafox-Sánchez CA; Cruz A; Marín-Rosales M; Muñoz-Valle JF
    Sci Rep; 2020 Apr; 10(1):6236. PubMed ID: 32277232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Redirecting T-cell Activity with Anti-BCMA/Anti-CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia and Other B-cell Lymphomas.
    Martens AWJ; Rietveld JM; de Boer R; Peters FS; Ngo A; van Mil LWHG; de Heer K; Spaargaren M; Verkleij CPM; van de Donk NWCJ; Adams HC; Eldering E; van Noesel CJM; Verona R; Kater AP
    Cancer Res Commun; 2022 May; 2(5):330-341. PubMed ID: 36875718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toll-like receptor 9 activation induces expression of membrane-bound B-cell activating factor (BAFF) on human B cells and leads to increased proliferation in response to both soluble and membrane-bound BAFF.
    Abu-Rish EY; Amrani Y; Browning MJ
    Rheumatology (Oxford); 2013 Jul; 52(7):1190-201. PubMed ID: 23436580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble B-cell maturation antigen in multiple myeloma.
    Costa BA; Ortiz RJ; Lesokhin AM; Richter J
    Am J Hematol; 2024 Apr; 99(4):727-738. PubMed ID: 38270277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.